Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
KNSA | US
0.26
1.36%
Healthcare
Biotechnology
31/03/2024
05/07/2024
19.36
19.06
19.44
18.96
Kiniksa Pharmaceuticals Ltd. a biopharmaceutical company focuses on discovering acquiring developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST an interleukin-1alpha and interleukin-1beta for the treatment of recurrent pericarditis which is an inflammatory cardiovascular disease; Mavrilimumab a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab a monoclonal antibody that completed Phase 2b clinical trial for the treatment of prurigo nodularis a chronic inflammatory skin condition; and KPL-404 a monoclonal antibody inhibitor of the CD40- CD154 interaction a T-cell co-stimulatory signal critical for B-cell maturation immunoglobulin class switching and type 1 immune response. Kiniksa Pharmaceuticals Ltd. was incorporated in 2015 and is based in Hamilton Bermuda.
View LessPositive Momentum
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
High Short-term Volatility
Smallcap (300M - 2B USD)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
36.5%1 month
31.4%3 months
29.7%6 months
34.5%143.62
-
2.78
0.03
0.02
-44.93
3.80
-
-28.33M
1.37B
1.37B
-
-20.71
550.00
65.20
2.11
16.59
15.02
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
2.06
Range1M
2.38
Range3M
3.96
Rel. volume
0.70
Price X volume
5.97M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Akero Therapeutics Inc | AKRO | Biotechnology | 21.45 | 1.48B | -2.19% | n/a | 4.28% |
Dynavax Technologies Corporation | DVAX | Biotechnology | 11.25 | 1.47B | 2.09% | 160.43 | 41.41% |
Array BioPharma Inc | ARRY | Biotechnology | 9.62 | 1.46B | -4.85% | 27.00 | 114.13% |
Avadel Pharmaceuticals plc | AVDL | Biotechnology | 14.78 | 1.42B | 1.72% | n/a | 46.87% |
MannKind Corporation | MNKD | Biotechnology | 5.13 | 1.40B | 1.99% | 130.50 | -162.73% |
Bicycle Therapeutics Limited | BCYC | Biotechnology | 20.21 | 1.39B | 3.22% | n/a | 12.31% |
Longboard Pharmaceuticals Inc. Common Stock | LBPH | Biotechnology | 34.87 | 1.36B | 9.28% | n/a | 1.27% |
Belite Bio Inc | BLTE | Biotechnology | 45.5 | 1.36B | -0.55% | n/a | 0.00% |
BioCryst Pharmaceuticals Inc | BCRX | Biotechnology | 6.52 | 1.35B | 1.72% | n/a | -173.65% |
Verona Pharma plc | VRNA | Biotechnology | 16.11 | 1.31B | 2.55% | n/a | 22.79% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Steelcase Inc | SCS | Building Products & Equipment | 12.82 | 1.46B | -0.93% | 17.05 | 69.98% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 13.45 | 1.31B | -0.37% | n/a | 20.15% |
REV Group Inc | REVG | Recreational Vehicles | 24.74 | 1.28B | -2.06% | 5.86 | 66.74% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.36 | 1.14B | 1.60% | n/a | -628.58% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 17.73 | 799.13M | -2.42% | n/a | 4070.84% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 32.65 | 667.35M | -2.74% | n/a | 4.21% |
Ennis Inc | EBF | Building Products & Equipment | 21.25 | 552.16M | -0.75% | 13.68 | 1.15% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 4.48 | 428.47M | -2.40% | n/a | 138.85% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 25.77 | 412.92M | -1.68% | n/a | 322.60% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.74 | 369.15M | -2.49% | 14.12 | 86.68% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -44.93 | -2.43 | Cheaper |
Ent. to Revenue | 3.80 | 4,101.76 | Cheaper |
PE Ratio | 143.62 | 41.26 | Expensive |
Price to Book | 2.78 | 22.34 | Cheaper |
Dividend Yield | - | 2.39 | - |
Std. Deviation (3M) | 29.67 | 76.52 | Lower Risk |
Debt to Equity | 0.03 | 0.51 | Cheaper |
Debt to Assets | 0.02 | 0.24 | Cheaper |
Market Cap | 1.37B | 3.77B | Emerging |